亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Potent antitumor activity of anti-HER2 antibody-topoisomerase I inhibitor conjugate based on self-immolative dendritic dimeric-linker

连接器 化学 体内 曲妥珠单抗 抗体-药物偶联物 结合 前药 癌症研究 药理学 抗体 癌症 单克隆抗体 生物化学 免疫学 医学 生物 内科学 乳腺癌 生物技术 数学 数学分析 操作系统 计算机科学
作者
Yulia Liubomirski,Galia Tiram,Anna Scomparin,Samer Gnaim,Sayantan Das,Sachin Popat Gholap,Liang Ge,Eilam Yeini,Omri Shelef,Arie Zauberman,Nir Berger,Doron Kalimi,Mira Toister‐Achituv,Christian J. Schröter,Stephan Dickgießer,Jason Tonillo,Min Shan,Carl Deutsch,Stanley Sweeney-Lasch,Doron Shabat
出处
期刊:Journal of Controlled Release [Elsevier BV]
卷期号:367: 148-157 被引量:18
标识
DOI:10.1016/j.jconrel.2024.01.025
摘要

Antibody-drug conjugates (ADCs) are a rapidly expanding class of anticancer therapeutics, with 14 ADCs already approved worldwide. We developed unique linker technologies for the bioconjugation of drug molecules with controlled-release applications. We synthesized cathepsin-cleavable ADCs using a dimeric prodrug system based on a self-immolative dendritic scaffold, resulting in a high drug-antibody ratio (DAR) with the potential to reach 16 payloads due to its dendritic structure, increased stability in the circulation and efficient release profile of a highly cytotoxic payload at the targeted site. Using our novel cleavable linker technologies, we conjugated the anti-human epidermal growth factor receptor 2 (anti-HER2) antibody, trastuzumab, with topoisomerase I inhibitors, exatecan or belotecan. The newly synthesized ADCs were tested in vitro on mammary carcinoma cells overexpressing human HER2, demonstrating a substantial inhibitory effect on the proliferation of HER2-positive cells. Importantly, a single dose of our trastuzumab-based ADCs administered in vivo to mice bearing HER2-positive tumors, showed a dose-dependent inhibition of tumor growth and survival benefit, with the most potent antitumor effects observed at 10 mg/kg, which resulted in complete tumor regression and survival of 100% of the mice. Overall, our novel dendritic technologies using the protease-cleavable Val-Cit linker present an opportunity for the development of highly selective and potent controlled-released therapeutic payloads. This strategy could potentially lead to the development of novel and effective ADC technologies for patients diagnosed with HER2-positive cancers. Moreover, our proposed ADC linker technology can be implemented in additional medical conditions such as other malignancies as well as autoimmune diseases that overexpress targets, other than HER2.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
舒心鞋垫完成签到,获得积分10
4秒前
华仔的应助被爱学习的doge采纳,获得10
12秒前
李爱国的应助被爱学习的doge采纳,获得50
12秒前
12秒前
赘婿的应助被爱学习的doge采纳,获得10
13秒前
小马甲的应助被爱学习的doge采纳,获得10
13秒前
13秒前
13秒前
Owen的应助被爱学习的doge采纳,获得10
13秒前
斯文败类的应助被爱学习的doge采纳,获得30
14秒前
华仔的应助被爱学习的doge采纳,获得10
14秒前
19秒前
20秒前
桐桐的应助被爱学习的doge采纳,获得10
21秒前
21秒前
21秒前
共享精神的应助被爱学习的doge采纳,获得10
21秒前
顾矜的应助被爱学习的doge采纳,获得10
21秒前
Owen的应助被爱学习的doge采纳,获得10
21秒前
molihuakai的应助被爱学习的doge采纳,获得10
21秒前
JamesPei的应助被爱学习的doge采纳,获得10
21秒前
英姑的应助被爱学习的doge采纳,获得10
21秒前
35秒前
Ccccn完成签到,获得积分10
40秒前
Voiceless发布了新的文献求助10
43秒前
44秒前
满意的平凡完成签到,获得积分10
49秒前
伶俐的秀发完成签到,获得积分10
50秒前
ChenYQ完成签到,获得积分10
1分钟前
苹果完成签到 ,获得积分10
1分钟前
殷勤的半凡完成签到,获得积分10
1分钟前
耍酷的手套完成签到,获得积分10
1分钟前
1分钟前
1分钟前
充电宝的应助被爱学习的doge采纳,获得10
1分钟前
1分钟前
1分钟前
1分钟前
orixero的应助被爱学习的doge采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179924
求助须知:如何正确求助?哪些是违规求助? 9570159
关于积分的说明 21808379
捐赠科研通 7775767
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557347
邀请新用户注册赠送积分活动 2478918